GLP-1 Obesity Drugs Show Heart-Benefit Breakthrough
New clinical trial data reveals significant cardiovascular protection, potentially redefining obesity treatment as preventive cardiology.
Novo Nordisk’s latest trial of semaglutide (Wegovy) has up...